0.605
0.02 (2.54%)
| Previous Close | 0.590 |
| Open | 0.596 |
| Volume | 668,984 |
| Avg. Volume (3M) | 8,073,593 |
| Market Cap | 16,849,084 |
| Price / Book | 8.34 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Diluted EPS (TTM) | -7.36 |
| Total Debt/Equity (MRQ) | 566.73% |
| Current Ratio (MRQ) | 1.99 |
| Operating Cash Flow (TTM) | -27.36 M |
| Levered Free Cash Flow (TTM) | -18.79 M |
| Return on Assets (TTM) | -48.51% |
| Return on Equity (TTM) | -576.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | KALA BIO, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA’smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.91% |
| % Held by Institutions | 64.18% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Jan 2026 | Announcement | KALA BIO Settles Approximately $10.6 million of Debt |
| 05 Dec 2025 | Announcement | KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules |
| 04 Dec 2025 | Announcement | KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |